11 results found.

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using fulvestrant; anastrozole

Alliance for Clinical Trials in Oncology - Recruiting 18 years or older.
- Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
fulvestrant; anastrozole

Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Recep Clinical Trial using nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Celgene Corporation - Recruiting 18 years or older.
- A Phase 2/3, Multi-center, Open-label, Randomized Study of Weekly Nab-paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to the Combination of Gemcitabine and Carboplatin, as First-line Treatment in Female Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer.
nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects; Carboplatin AUC 2; gemcitabine 1000 mg

Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breas Clinical Trial using therapeutic conventional surgery; radiation therapy; quality-of-life assessment

Roswell Park Cancer Institute - Recruiting 50 years or older.
- Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer.
therapeutic conventional surgery; radiation therapy; quality-of-life assessment

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using zoledronic acid; laboratory biomarker analysis; therapeutic conventional surgery

City of Hope Medical Center - Recruiting N/A or older.
- A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer.
zoledronic acid; laboratory biomarker analysis; therapeutic conventional surgery

Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Clinical Trial using cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer.
cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941

Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Ca Clinical Trial using systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE III, RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/-CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR-POSITIVE AND HER2-NEGATIVE BREAST CANCER WITH RECURRENCE SCORE (RS) OF 25 OR LESS. RXPONDER: A CLINICAL TRIAL RX FOR POSITIVE NODE, ENDOCRINE RESPONSIVE BREAST CANCER.
systemic chemotherapy; tamoxifen citrate; anastrozole; exemestane; letrozole

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using Paclitaxel; Carboplatin; Doxorubicin; Cyclophosphamide; Veliparib

Thomas Jefferson University - Recruiting 18 years or older.
- An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer.
Paclitaxel; Carboplatin; Doxorubicin; Cyclophosphamide; Veliparib

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

University of Washington - Recruiting 18 years or older.
- Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.
veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors.
veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer.
dinaciclib; epirubicin hydrochloride; laboratory biomarker analysis